968 related articles for article (PubMed ID: 34298991)
21. Involvement of CXCR4/CXCR7/CXCL12 Interactions in Inflammatory bowel disease.
Werner L; Guzner-Gur H; Dotan I
Theranostics; 2013; 3(1):40-6. PubMed ID: 23382785
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
23. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.
Circelli L; Sciammarella C; Guadagno E; Tafuto S; del Basso de Caro M; Botti G; Pezzullo L; Aria M; Ramundo V; Tatangelo F; Losito NS; Ieranò C; D'Alterio C; Izzo F; Ciliberto G; Colao A; Faggiano A; Scala S
Oncotarget; 2016 Apr; 7(14):18865-75. PubMed ID: 26934559
[TBL] [Abstract][Full Text] [Related]
24. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.
Zabel BA; Wang Y; Lewén S; Berahovich RD; Penfold ME; Zhang P; Powers J; Summers BC; Miao Z; Zhao B; Jalili A; Janowska-Wieczorek A; Jaen JC; Schall TJ
J Immunol; 2009 Sep; 183(5):3204-11. PubMed ID: 19641136
[TBL] [Abstract][Full Text] [Related]
25. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.
Ieranò C; Santagata S; Napolitano M; Guardia F; Grimaldi A; Antignani E; Botti G; Consales C; Riccio A; Nanayakkara M; Barone MV; Caraglia M; Scala S
Cell Death Dis; 2014 Jul; 5(7):e1310. PubMed ID: 24991762
[TBL] [Abstract][Full Text] [Related]
26. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands.
Luker KE; Steele JM; Mihalko LA; Ray P; Luker GD
Oncogene; 2010 Aug; 29(32):4599-610. PubMed ID: 20531309
[TBL] [Abstract][Full Text] [Related]
27. G protein‑mediated EGFR transactivation is a common mechanism through which the CXCL12 receptors, CXCR4 and CXCR7, control human cancer cell migration.
Zieger-Naumann K; Kuhl F; Engele J
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38099418
[TBL] [Abstract][Full Text] [Related]
28. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases.
Liepelt A; Tacke F
Am J Physiol Gastrointest Liver Physiol; 2016 Aug; 311(2):G203-9. PubMed ID: 27313175
[TBL] [Abstract][Full Text] [Related]
29. Effects of the chemokine CXCL12 and combined internalization of its receptors CXCR4 and CXCR7 in human MCF-7 breast cancer cells.
Hattermann K; Holzenburg E; Hans F; Lucius R; Held-Feindt J; Mentlein R
Cell Tissue Res; 2014 Jul; 357(1):253-66. PubMed ID: 24770893
[TBL] [Abstract][Full Text] [Related]
30. Rapid uptake and degradation of CXCL12 depend on CXCR7 carboxyl-terminal serine/threonine residues.
Hoffmann F; Müller W; Schütz D; Penfold ME; Wong YH; Schulz S; Stumm R
J Biol Chem; 2012 Aug; 287(34):28362-77. PubMed ID: 22736769
[TBL] [Abstract][Full Text] [Related]
31. Expression and function of the SDF-1 chemokine receptors CXCR4 and CXCR7 during mouse limb muscle development and regeneration.
Hunger C; Ödemis V; Engele J
Exp Cell Res; 2012 Oct; 318(17):2178-90. PubMed ID: 22766125
[TBL] [Abstract][Full Text] [Related]
32. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells.
Boudot A; Kerdivel G; Habauzit D; Eeckhoute J; Le Dily F; Flouriot G; Samson M; Pakdel F
PLoS One; 2011; 6(6):e20898. PubMed ID: 21695171
[TBL] [Abstract][Full Text] [Related]
33. Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.
Jaracz-Ros A; Bernadat G; Cutolo P; Gallego C; Gustavsson M; Cecon E; Baleux F; Kufareva I; Handel TM; Bachelerie F; Levoye A
J Leukoc Biol; 2020 Jun; 107(6):1123-1135. PubMed ID: 32374043
[TBL] [Abstract][Full Text] [Related]
34. Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7.
Luker K; Gupta M; Luker G
Biotechniques; 2009 Jul; 47(1):625-32. PubMed ID: 19594447
[TBL] [Abstract][Full Text] [Related]
35. Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer.
Zhu X; Bai Q; Lu Y; Lu Y; Zhu L; Zhou X; Wu L
Int J Oncol; 2016 Jun; 48(6):2321-9. PubMed ID: 27082011
[TBL] [Abstract][Full Text] [Related]
36. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
37. Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma.
Liberman J; Sartelet H; Flahaut M; Mühlethaler-Mottet A; Coulon A; Nyalendo C; Vassal G; Joseph JM; Gross N
PLoS One; 2012; 7(8):e43665. PubMed ID: 22916293
[TBL] [Abstract][Full Text] [Related]
38. The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers.
Freitas C; Desnoyer A; Meuris F; Bachelerie F; Balabanian K; Machelon V
Cytokine Growth Factor Rev; 2014 Jun; 25(3):307-16. PubMed ID: 24853339
[TBL] [Abstract][Full Text] [Related]
39. CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma.
Chen N; Jiang X; Wang J; Wu T; Cheng B; Xia J
Tumour Biol; 2016 Jan; 37(1):567-75. PubMed ID: 26232325
[TBL] [Abstract][Full Text] [Related]
40. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]